Who sells aclaris Therapeutics (ACL) stock?
Company insiders that have sold Aclaris Therapeutics company stock in the last year include David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson, and Neal Walker. View insider buying and selling activity for Aclaris Therapeutics or view top insider-selling stocks.
What is the upside for aclaris Therapeutics'stock?
Their forecasts range from $26.00 to $50.00. On average, they expect Aclaris Therapeutics' stock price to reach $36.00 in the next year. This suggests a possible upside of 168.7% from the stock's current price. View analysts' price targets for Aclaris Therapeutics or view top-rated stocks among Wall Street analysts.
Will aclaris Therapeutics stock outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe ACRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Aclaris Therapeutics does not currently pay a dividend. Aclaris Therapeutics does not have a long track record of dividend growth.
Who is the CEO of aclaris?
Neal Walker, the President and CEO of Aclaris, will participate in a virtual fireside chat which will be available beginning on Thursday, November 18 Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021.
See more
Should I buy or sell Aclaris Therapeutics stock right now?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 buy...
What is Aclaris Therapeutics' stock price forecast for 2022?
6 Wall Street research analysts have issued 1-year target prices for Aclaris Therapeutics' shares. Their forecasts range from $26.00 to $50.00. On...
How has Aclaris Therapeutics' stock performed in 2022?
Aclaris Therapeutics' stock was trading at $14.54 at the start of the year. Since then, ACRS stock has decreased by 0.7% and is now trading at $14....
Are investors shorting Aclaris Therapeutics?
Aclaris Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 3,520,000 shares,...
When is Aclaris Therapeutics' next earnings date?
Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.31) EP...
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the following people: Dr. Neal S. Walker D.O. , Co-Founder, CEO, Pres & Director (Age 52, Pay $96...
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?
1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com . Neal Walker has an approval rating of 100% among Aclaris Therapeuti...
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include Cerevel Therapeutics (CERE) , Turning Point Therapeutics (TPTX) , Galapagos (GLP...
Is Aclaris Therapeutics stock a Buy, Sell or Hold?
Aclaris Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 0 hold ratings, and 0...
What was the 52-week low for Aclaris Therapeutics stock?
The low in the last 52 weeks of Aclaris Therapeutics stock was 9.27. According to the current price, Aclaris Therapeutics is 156.20% away from the...
What was the 52-week high for Aclaris Therapeutics stock?
The high in the last 52 weeks of Aclaris Therapeutics stock was 23.98. According to the current price, Aclaris Therapeutics is 60.38% away from the...
What are analysts forecasts for Aclaris Therapeutics stock?
The 5 analysts offering price forecasts for Aclaris Therapeutics have a median target of 33.40, with a high estimate of 50.00 and a low estimate of...
About Aclaris Therapeutics
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.
50 Biggest Movers From Yesterday
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aclaris Therapeutics stock. View analyst ratings for Aclaris Therapeutics or view top-rated stocks.
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for PTSD treatment.
